Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence.
Bottom Line: Colorectal carcinoma (CRC) constitutes a common malignancy with limited therapeutic options in metastasized stages.We generated TRAIL-MSC by transduction of human MSC with a third generation lentiviral vector system and analysed their characteristics and capacity to inhibit CRC growth. (1) TRAIL-MSC showed stable transgene expression with neither changes in the defining MSC characteristics nor signs of malignant transformation. (2) Upon direct in vitro coculture TRAIL-MSC induced apoptosis in TRAIL-sensitive CRC-cell lines (DLD-1 and HCT-15) but also in CRC-cell lines resistant to soluble TRAIL (HCT-8 and SW480). (3) In mixed subcutaneous (s.c.) xenografts TRAIL-MSC inhibited CRC-tumour growth presumably by apoptosis induction but a substantial proportion of TRAIL-MSC within the total tumour cell number was needed to yield such anti-tumour effect. (4) Systemic application of TRAIL-MSC had no effect on the growth of s.c.DLD-1 xenografts.
Affiliation: Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.Show MeSH
Related in: MedlinePlus
Mentions: In comparison to controls receiving no MSC a similar tumour growth occurred in mice receiving WT-MSC as well as in mice receiving TRAIL-MSC (Fig. 6A). No signs of toxicity were seen upon systemic transplantation of TRAIL-MSC. In particular no organ dysfunction and no formation of additional tumours were observed upon live observation of animals and macroscopic inspection after killing.
Affiliation: Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.